(43) International Publication Date WO 2005/044187 A3 19 May 2005 (19.05.2005)

A61K 9/14.

English

English

(10) International Publication Number

- (51) International Patent Classification7: A01N 25/02, 25/00
- (21) International Application Number:
- PCY/US2004/035129
- (22) International Filing Date: 22 October 2004 (22.10.2004)
- (25) Filing Language:
- (26) Publication Language:
- (30) Priority Data:
- 60/515,077 28 October 2003 (28.10.2003) US
- (71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).
- (71) Applicant (for MG only): SMITHKLINE BEECHAM CORPORATION (US/US); One Franklin Plaza, PO Box 7929. Philadelphia, PA 19101 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): DAWSON. Michelle, L. [GB/GB]; GlaxoSmithKline, Park Road, Ware, Hertfordshire SG12 0DP (GB), ROCHE, Trevor, C. [GB/GB]; GlaxoSmithKline, Park Road, Ware, Hertfordshire SG12 ODP (GB), WHITAKER, Mark [GB/GB]; GlaxoSmithKlinc, Park Road, Ware, Hertfordshire SG12 0DP (GB). CHIDAVAENZI, Owen, Chisora [ZW/GB]; GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 ODP (GB).
- (74) Agents: LEVY, David, J. et al.; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG. PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ. TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG).


Published:

- with international search report
 - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 23 March 2006


For two letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: INHALABLE PHARMACEUTICAL FORMULATIONS EMPLOYING LACTOSE ANHYDRATE AND METHODS OF ADMINISTERING THE SAME

Salmeterol



Fluticasone propionate



Legend (%/type Anhydrous Lactose) -- 1% Commercial - -- - 1% Stable

----- 10% Commercial - -A- - 10% Stable -- 50% Commercial -- -- -- 60% Stable ------- 1% Hygroscopic · · · A· · · 10% Hygroscopic — K — Monohydrate 2

(57) Abstract: Pharmaceutical formulations suitable for inhalation comprise at least one pharmaceutically active medicament and lactose anhydrate.

INTERNATIONAL SEARCH REPORT

International application No.

	PC	T/US04/35129
A. CLASSIFICATION OF SUBJECT MATTER		
IPC(7) : A61K 9/14; A01N 25/02, 25/00		
US CL : 424/489, 43, 46; 514/826, 951		
According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) U.S.: 424/489, 43, 46; 514/826, 951		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WEST, EAST, MEDLINE		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category * Citation of document, with indication, where a	ppropriate, of the relevant p	assages Relevant to claim No.
X US 6,495,167 B2 (YANG) 17 December 2002 (17.1)		
		19-28, 31-32, 34, 36- 37, 39-47, 50-51, 53, 55, 56
		9-10, 13, 15, 18, 29-30 33, 35, 38, 48-49, 52, 54, 57
X US 6,482,417 B2 (LEIBOVICI et al) 19 November 2002 (19.11.2002), Table 1.		1-6 and 18-21
		-
Further documents are listed in the continuation of Box C.	See patent fami	ly annex.
 Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance 	date and not in cor	blished after the international filing date or priority iffict with the application but cited to understand the underlying the invention
"E" earlier application or patent published on or after the international filing date		salar relevance; the claimed invention cannot be or cannot be considered to involve an inventive step at is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" decument of particular relevance; the claimed investion cannot be considered to involve as inventive step when the document is combined with one or mote other such documents, such combination	
"O" document referring to an oral disclosure, use, exhibition or other means	being obvious to a	e or more other such documents, such combination person skilled in the art
"P" document published prior to the international filing date but later than the priority date claimed	"&" document member	of the same patent family
Date of the actual completion of the international search	Date of mailing of the int	ernational scarch report
_11 December 2005 (11.12.2005)		31 JAN 2006
Name and mailing address of the ISA/US	Authorized offices	. 17
Mail Stop PCT, Attn: ISA/US Commissioner for Patents	S. Gollamudi W	ellucation
P.O. Box 1450	Telephone No. (703) 308-0196	
Alexandria, Virginia 22313-1450 Telephone No. (2013) 308-0196		
orm PCT/ISA/210 (second sheet) (April 2005)		